Ozempic among ‘bogus’ drug patents being challenged by U.S. to spur competition

The Federal Trade Commission sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. : Health